Back to top
more

Ayala Pharmaceuticals, Inc. (ADXS)

(Delayed Data from OTC)

$0.57 USD

0.57
220

0.00 (0.00%)

Updated Apr 22, 2024 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ADXS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Ayala Pharmaceuticals, Inc. [ADXS]

Reports for Purchase

Showing records 1 - 20 ( 96 total )

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

12/08/2019

Company Report

Pages: 6

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ADXS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

06/12/2019

Company Report

Pages: 6

ADXS-HOT Readout in 2H19; Clinical Hold on AIM2CERV Lifted; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

04/05/2019

Company Report

Pages: 11

ADXS-PSA and ADXS-NEO Show Promise at AACR, but Questions Remain; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

03/13/2019

Company Report

Pages: 6

Eyes on ADXS-NEO Data at AACR; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

02/15/2019

Daily Note

Pages: 3

ADXS-HOT Program Initiated in NSCLC; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

01/24/2019

Daily Note

Pages: 3

AXAL Placed Under Partial Clinical Hold; Expect Delays to AIM2CERV; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

01/16/2019

Company Report

Pages: 6

Eyes on ADXS-NEO Data in 1Q19; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

12/18/2018

Company Report

Pages: 7

Amgen Withdrawal Puts ADXS-NEO in Limbo; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

11/06/2018

Company Report

Pages: 6

AIM2CERV to Resume With Potential Readout in 2020; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

09/12/2018

Company Report

Pages: 6

ADXS-NEO and ADXS-HOT Programs to Report in 2019; Lower $2.00PT on Dilution; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

07/11/2018

Daily Note

Pages: 3

Eyes on ADXS-NEO and ADXS-HOT After Axal Withdrawal; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

06/08/2018

Company Report

Pages: 7

A Strategic Shift to Focus on ADXS-NEO and ADXS-HOT; Lower PT to $3.00; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

04/17/2018

Daily Note

Pages: 5

ADXS-NEO Can Incite Immune Responses With "Non-Immunogenic" Antigens; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

03/14/2018

Company Report

Pages: 7

Clinical Hold Is Likely Temporary; Lower $6PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

02/21/2018

Industry Report

Pages: 6

Three Notable Areas of Development in Companion Animal Health; Our Takeaways from VMX 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

12/27/2017

Company Report

Pages: 6

First Lm-LLO Product Approved for Pets; Looking Ahead to 2018; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/08/2017

Daily Note

Pages: 3

Management Reaffirms Development Strategy; Clinical Updates in 2018; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

09/15/2017

Company Report

Pages: 6

Pipeline Restructured to Focus on Lead Programs; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Ayala Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

09/01/2017

Industry Report

Pages: 8

A Wind of Change Is Blowing Through the Animal Health Market

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party